KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Accumulated Expenses: 2015-2024

Historic Other Accumulated Expenses for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to $10.4 million.

  • CRISPR Therapeutics AG's Other Accumulated Expenses fell 88.33% to $563,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $563,000, marking a year-over-year decrease of 88.33%. This contributed to the annual value of $10.4 million for FY2024, which is 102.63% up from last year.
  • According to the latest figures from FY2024, CRISPR Therapeutics AG's Other Accumulated Expenses is $10.4 million, which was up 102.63% from $5.1 million recorded in FY2023.
  • CRISPR Therapeutics AG's Other Accumulated Expenses' 5-year high stood at $10.4 million during FY2024, with a 5-year trough of $1.2 million in FY2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median Other Accumulated Expenses value was $5.1 million (recorded in 2023), while the average stood at $5.6 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 82.45% in 2021, then soared by 341.67% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Other Accumulated Expenses (Yearly) stood at $7.2 million in 2020, then plummeted by 82.45% to $1.3 million in 2021, then declined by 7.98% to $1.2 million in 2022, then surged by 341.67% to $5.1 million in 2023, then skyrocketed by 102.63% to $10.4 million in 2024.